DrugCendR Inc.   Report issue

For profit Phase 1
Founded: La Jolla CA United States (2016)

Organization Overview

First Clinical Trial
2018
NCT03517176
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

DrugCendR Inc.

Active Ingredients

Drugs in Phase 1 Trials (3)

cend-1 (1 trial)

gemcitabine (gemzar) (1 trial)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Pancreatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 3